Idiopathic Pulmonary Fibrosis: all 565 studies
Page 5 of 6. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.
- Traditional Chinese Medicine(TCM) Syndrome Classification of Idiopathic Pulmonary Fibrosis(IPF) and MetabolomicsCompletedNCT03711435
- Evolution of Lung 18FDG Uptake in Patients With Idiopathic Pulmonary Fibrosis and Receiving PirfenidoneStatus unknownNCT03692481Not applicable
- Acute Effects of Oxygen Supplementation Among IPF PatientsCompletedNCT03688334Not applicable
- It's Not JUST Idiopathic Pulmonary Fibrosis StudyStatus unknownNCT03670576
- Idiopathic Pulmonary Fibrosis Registry China StudyStatus unknownNCT03666234
- To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy VolunteersCompletedNCT03650075Phase 1
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy AdultsCompletedNCT03619616Phase 1
- A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)WithdrawnNCT03591926Phase 2
- Respiratory Muscle Strength in Patients With Idiopathic Pulmonary FibrosisCompletedNCT03588260
- Supporting Adherence to Pirfenidone in Patients With Idiopathic Pulmonary FibrosisCompletedNCT03567785
- Continuation of Nintedanib After Single Lung Transplantation in IPF SubjectsTerminatedNCT03562416Phase 2
- Effects of Whole Body Vibration Training in Patients With Interstitial Lung DiseaseStatus unknownNCT03560154Not applicable
- Feasibility & Effect of a Tele-rehabilitation Program in Idiopathic Pulmonary Fibrosis (IPF)Status unknownNCT03548181Phase 2
- The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female SubjectsCompletedNCT03502902Phase 1
- Muscle Stimulation in Advanced Idiopathic Pulmonary FibrosisCompletedNCT03499275Not applicable
- Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular CharacterizationStatus unknownNCT03486262
- Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary FibrosisTerminatedNCT03480451Not applicable
- Status and Develepment Mental Quality of Life COPD/IPF Inpatients Before and After Pulmonary RehabilitationTerminatedNCT03477526Not applicable
- Detection of Early Idiopathic Pulmonary FibrosisActive, not recruitingNCT03457935
- Assessment of Skeletal Muscle Dysfunction in Patient With Idiopathic Pulmonary FibrosisStatus unknownNCT03440489Not applicable
- Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of LifeCompletedNCT03420235Not applicable
- Effects of Oxymizer Pendant Cannula Versus Conventional Nasal Cannula During Endurance Shuttle Walk Tests in Hypoxemic Patients With Idiopathic Pulmonary FibrosisCompletedNCT03411876Not applicable
- Comparing Measurements Made in an Incremental Shuttle Walk Test and a Cardiopulmonary Exercise Test in Patients With IPFStatus unknownNCT03360032
- Pulmonary Rehabilitation in Idiopathic Pulmonary FibrosisCompletedNCT03326089Not applicable
- Toward Self-management in ILDCompletedNCT03300583
- Clinical Trial of Chinese Herbal Medicine for Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03274544Not applicable
- Idiopathic Pulmonary Fibrosis (IPF) and the 3 Minutes Sit-to-stand TestCompletedNCT03268915Not applicable
- Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary FibrosisWithdrawnNCT03258801
- Impact of a Systematic Palliative Care on Quality of Life, in Advanced Idiopathic Pulmonary Fibrosis.Status unknownNCT03229343Not applicable
- Structured Exercise Training Programme in Idiopathic Pulmonary FibrosisCompletedNCT03222648Not applicable
- Prevalence and Impact on Quality of Life of Airway Disease in Patients With Idiopathic Pulmonary FibrosisStatus unknownNCT03215147
- Idiopathic Pulmonary Fibrosis Job Exposures StudyCompletedNCT03211507
- Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CTCompletedNCT03183570Early Phase 1
- Characteristics and Health Related Quality of Life in Idiopathic Pulmonary FibrosisStatus unknownNCT03171870Not applicable
- Quality of Life Study in Participants With IPF Under Pirfenidone TreatmentCompletedNCT03115619
- The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female SubjectsCompletedNCT03092102Phase 1
- Lung MRI in the Management of Idiopathic Pulmonary FibrosisCompletedNCT03078426Not applicable
- Short-term Effects of Supplemental Oxygen in Patients With IPFCompletedNCT03050255Not applicable
- Clinical Course of Interstitial Lung Diseases: European IPF Registry and BiobankActive, not recruitingNCT02951416
- Integrating Palliative Care for Patients With Idiopathic Pulmonary Fibrosis and Their CaregiversCompletedNCT02929017Not applicable
- The Coagulation Cascade in Idiopathic Pulmonary FibrosisStatus unknownNCT02885961Not applicable
- Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human TrialCompletedNCT02874989Phase 1
- Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary FibrosisActive, not recruitingNCT02848625Not applicable
- Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)Status unknownNCT02827734
- Turkish Thoracic Society Usual Interstitial Pneumonia Registry StudyTerminatedNCT02821039
- Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nationwide Follow-upCompletedNCT02818712
- Early Diagnosis of Pulmonary Fibrosis - Diagnostic DelayActive, not recruitingNCT02772549
- Pulmonary Fibrosis Foundation Patient RegistryCompletedNCT02758808
- Pulmonary Fibrosis Biomarker Cohort - a Prospective Cohort of Incident Patients With IPFActive, not recruitingNCT02755441
- Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary FibrosisCompletedNCT02745184Phase 1/2
- Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary FibrosisCompletedNCT02739165Phase 3
- Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02699879
- A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary FibrosisCompletedNCT02648048Phase 1
- Validation of the Risk Stratification Score in Idiopathic Pulmonary FibrosisCompletedNCT02632123
- Exhaled Breath Condensate Biomarkers and Cough in IPFCompletedNCT02630940
- Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)CompletedNCT02622477
- First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis PatientsCompletedNCT02612051Phase 1
- Home-Based Pulmonary Rehab for Patients With Pulmonary FibrosisCompletedNCT02600689Not applicable
- Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial PneumoniasCompletedNCT02596841
- Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung DiseaseCompletedNCT02594839Phase 1/2
- Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary FibrosisCompletedNCT02594059Not applicable
- Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in CanadaCompletedNCT02552849
- High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With NintedanibCompletedNCT02551068Not applicable
- A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02538536Phase 2
- Responsiveness and MID of 4 Metre Gait Speed in Idiopathic Pulmonary FibrosisCompletedNCT02530736
- 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary FibrosisStatus unknownNCT02485886Early Phase 1
- Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary FibrosisCompletedNCT02478268Phase 1
- Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary FibrosisCompletedNCT02460588Phase 3
- Reliability of the 4 Metre Gait Speed in Idiopathic Pulmonary FibrosisCompletedNCT02445157
- Breath Analysis in Lung FibrosisCompletedNCT02437448
- The Predictive Ability of 4MGS in IPFCompletedNCT02436278
- PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership CohortActive, not recruitingNCT02407431
- Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male SubjectsStatus unknownNCT02397005Phase 1
- Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary FibrosisCompletedNCT02315586
- Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)CompletedNCT02268981Not applicable
- 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPFCompletedNCT02267655Phase 1
- Auto-titrating Oxygen in Chronic Respiratory FailureCompletedNCT02248064Not applicable
- Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary FibrosisNo longer availableNCT02230982
- Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary FibrosisWithdrawnNCT02187393
- Modelling of Quality Life, Clinical and Physiological Measures in Idiopathic Pulmonary FibrosisStatus unknownNCT02176707
- Azithromycin in Idiopathic Pulmonary FibrosisCompletedNCT02173145Not applicable
- Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)Approved for marketingNCT02171156
- A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)WithdrawnNCT02168530Phase 2
- Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary FibrosisCompletedNCT02151435
- Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to PirfenidoneApproved for marketingNCT02141087
- Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisCompletedNCT02136992Phase 2
- Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary FibrosisStatus unknownNCT02135380Phase 1/2
- Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02085018Phase 2
- Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) PatientsCompletedNCT02058602Phase 1
- Nandrolone Decanoate in the Treatment of TelomeropathiesCompletedNCT02055456Phase 1/2
- A Validation and Dosimetry Study of GSK2634673F PET LigandTerminatedNCT02052297Phase 1
- Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary FibrosisCompletedNCT02048644Phase 2
- Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)TerminatedNCT02013700Phase 1
- The Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary FibrosisCompletedNCT02009293
- Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary FibrosisCompletedNCT01919827Phase 1
- Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With IPFCompletedNCT01874223
- Cromolyn Detection of Silent AspirationTerminatedNCT01841307Phase 1
- Study of Default Options in Advance DirectivesCompletedNCT01817686Not applicable
- The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung DiseaseStatus unknownNCT01809574
- Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With CotrimoxazoleTerminatedNCT01777737Phase 3